MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$17,803K
EPS
-$0.35
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Research and development
12,850
7,998*
10,328
6,121
General and administrative
-
5,490*
6,478
5,671
Selling, general and administrative
5,934
-
-
-
Total operating expenses
18,784
13,487
16,806
11,792
Net operating loss
-18,784
-13,487*
-16,806
-11,792
Interest income
981
863*
1,017
954
Interest expense
-
0*
-
-
Other expense, net
0
3*
-15
-9
Net loss
-17,803
-12,622
-15,804
-10,847
Basic EPS
-0.35
-0.329
-0.4
-0.27
Diluted EPS
-0.35
-0.329
-0.4
-0.27
Basic Average Shares
50,869,259
38,338,151
39,741,404
39,572,177
Diluted Average Shares
50,869,259
38,338,151
39,741,404
39,572,177
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$17,803K
(-64.13%↓ Y/Y)
Interest income
$981K
(2.83%↑ Y/Y)
Net operating loss
-$18,784K
(-59.29%↓ Y/Y)
Total operating
expenses
$18,784K
(59.29%↑ Y/Y)
Research and development
$12,850K
(109.93%↑ Y/Y)
Selling, general and
administrative
$5,934K
Buy us a coffee
TENAX THERAPEUTICS, INC. (TENX)
TENAX THERAPEUTICS, INC. (TENX)